Halozyme Therapeutics, Inc.
HALO
$63.65
-$1.48-2.27%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -203.34% | 27.89% | 77.12% | 53.72% | 60.46% |
| Total Depreciation and Amortization | 30.69% | 0.29% | 0.84% | 1.20% | -1.34% |
| Total Amortization of Deferred Charges | 5.75% | 0.92% | 0.93% | 0.87% | 0.88% |
| Total Other Non-Cash Items | 5,630.84% | 289.73% | -81.38% | -29.45% | -130.05% |
| Change in Net Operating Assets | -137.17% | -8.05% | -11.86% | -65.34% | 197.21% |
| Cash from Operations | 22.73% | 54.80% | 78.71% | 19.16% | 74.36% |
| Capital Expenditure | 53.24% | -99.74% | 39.47% | 73.20% | -17.57% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -144.25% | 223.30% | 318.85% | -13.06% | 671.24% |
| Cash from Investing | -2,616.24% | 220.38% | 301.69% | -9.36% | 455.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 15.65% | -11.21% | -87.32% | -- | 50.63% |
| Repurchase of Common Stock | 100.00% | -- | -- | -579.14% | 0.91% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 197.20% | -220.69% | -3,252.98% | -579.14% | 1.40% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -636.31% | 1,166.61% | -592.61% | 30.74% | 75.32% |